The review found no eligible studies for this question.
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).
It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).